Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer.
- Author:
Ming TONG
1
;
Zhong XU
;
Jun-kui AI
;
Yi-ming YUAN
;
Yi YIN
;
Jun-qi WANG
;
Hong-wei LI
;
Jian-he LIU
;
Dian-qi XIN
;
Li-qun ZHOU
;
Ming LI
;
Yan-qun NA
Author Information
- Publication Type:Journal Article
- MeSH: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; genetics; Aged; Aged, 80 and over; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Prostate-Specific Antigen; blood; Prostatic Hyperplasia; genetics; Prostatic Neoplasms; blood; genetics; pathology
- From: Chinese Journal of Surgery 2004;42(24):1493-1496
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEThe correlation were studied between testosterone 5-alpha-reductase II (SRD5A2) gene polymorphisms and prognosis factors.
METHODSV89L and A49T variants was identified with Mwo1 and Rsa1. The differences of V89L and A49T between cancer of prostate (CaP) and benign prostatic hyperplasia (BPH) were studied. In addition, we also researched the association of polymorphisms with age of onset, free prostate specific antigen (FPSA), total PSA (TPSA), FPSA/TPSA (F/T), Gleason score, and T stage in cancer group.
RESULTSWe found no differences of V89L and A49T polymorphisms between CaP and BPH. In CaP group the A49T variant was associated with lower age of onset (P = 0.03) and higher Gleason score (P = 0.015). There were no differences between VV and VL+LL polymorphisms with any of the characteristics studied. When the characteristics above were regarded as two-level discrete variable, there were no differences by A49T and V89Lvariants.
CONCLUSIONIn CaP group, the AT+TT genotype was perhaps associated with poor prognosis. VL+LL genotype has no relation with prognosis.
